ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION March 11, 2026
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia March 10, 2026
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy February 9, 2026
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program February 3, 2026
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care February 2, 2026
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency October 21, 2025
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development October 7, 2025
